Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma
Authors:
- 4 April 2019
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (10) , 2878-2892
Abstract
PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer.Keywords
This publication has 33 references indexed in Scilit:
- Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinomaOncology Letters, 2013
- DIANA-microT web server v5.0: service integration into miRNA functional analysis workflowsNucleic Acids Research, 2013
- GeneFriends: An online co-expression analysis tool to identify novel gene targets for aging and complex diseasesBMC Genomics, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Inhibition of Homologous Recombination by the PCNA-Interacting Protein PARIMolecular Cell, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The MicroRNA miR-139 Suppresses Metastasis and Progression of Hepatocellular Carcinoma by Down-regulating Rho-Kinase 2Gastroenterology, 2011
- Towards a knowledge-based Human Protein AtlasNature Biotechnology, 2010
- C12orf48, termed PARP‐1 binding protein, enhances poly(ADP‐ribose) polymerase‐1 (PARP‐1) activity and protects pancreatic cancer cells from DNA damageGenes, Chromosomes and Cancer, 2010
- Gain of 1q25–32, 12q23–24.3, and 17q12–22 facilitates tumorigenesis and progression of human squamous cell lung cancerThe Journal of Pathology, 2006